256

CB1954(Tretazicar (NSC-115829)), an anticancer prodrug, is activated by NAD(P)H quinone oxidoreductase 2. It is converted in the presence of the enzyme NQO2 and co-substrate caricotamide ( EP-0152R) (EP) into a potent cytotoxic bifunctional alkylating agent.

NDSB-256 (3-(Benzyldimethylammonio)propane-1-sulfonate) is a non-detergent sulfobetaine that prevents protein aggregation and increases the isomerization rate in a concentration-dependent manner.

Antibacterialagent 256 (Compound C09) is an inhibitor of Type I signal peptidase (SPase I). It targets Gram-positive bacteria, effectively inhibiting S. aureus ATCC 29213, E. faecium QF31, E. faecalis SF23-1, and S. suis P1 7, with MIC values ranging from 1-16 μg mL. In cancer cells HEp-2 and Caco-2, Antibacterialagent 256 exhibits cytotoxicity with CC50 values of 14.65 μg mL and 21.93 μg mL, respectively. Additionally, it shows hemolytic activity on mouse red blood cells with an HC50 of 13.29 μg mL and can improve MRSA skin infections in mouse models.

H 256 is a pepsin heptapeptide inhibitor.

PTZ-256 is a phenothiazine derivative with chemical name: 3-(10H-phenothiazin-10-yl)propane-1-amine. PTZ-256 has molecule weight 256, therefore, we call it as PTZ-256.

YG 19-256 is a biochemical.

NDSB 256-4T is a non-detergent sulfobetaine compound. It inhibits protein aggregation and aids in protein folding by interacting with early folding intermediates.

AGI-25696 is an inhibitor of methionine adenosyltransferase 2A (MATA2). AGI-25696 blocks the growth of MTAP-deleted tumors in vivo and can be used for studies about the treatment of cancer.

G256 HCl has antiarrhythmic and anti-ischemic activity.

BIX 02565 is a potent inhibitor of ribosomal S6 kinase 2 (RSK2, IC50: 1.1 nM).

Compound Fr12256, with CAS No. 10241-97-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12256 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr12565, with CAS No. 3696-23-9, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12565 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr12569, with CAS No. 27104-73-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12569 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound PDK0256, with CAS No. 530-48-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0256 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr12560, with CAS No. 175696-74-9, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12560 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr12561, with CAS No. 95337-78-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12561 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr12567, with CAS No. 63968-85-4, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12567 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr12568, with CAS No. 15644-93-6, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12568 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr13256, with CAS No. 166438-80-8, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr13256 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

KR-32568 is a sodium/hydrogen exchanger 1 (NHE-1) inhibitor (IC50: 230 nM) with potent cardioprotective effects. At a concentration of 10 μM, it restored cardiac systolic function in an isolated ischemic rat heart model. Additionally, KR-32568 (0.3 mg/kg) reduced myocardial infarction size in a rat model of ischemia and reperfusion injury.

ACTH 1-14 acetate(25696-21-3 free base) (Adrenocorticotropic Hormone Fragment 1-14 acetate) is a fragment of adrenocorticotrophin, which regulates cortisol and androgen production.Adrenocorticotropic hormone (ACTH), also known as corticotropin, is produced and secreted by the anterior pituitary gland. ACTH is an important component of the hypothalamic-pituitary-adrenal axis as a response to biological stress.

Compound 119256-40-5, with CAS No. 119256-40-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 119256-40-5 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

MK256 is a novel CDK8 inhibitor that demonstrates potent antitumor activity against AML by inhibiting the STAT pathway. It induces differentiation and maturation while inhibiting proliferation in AML cell lines. MK256 decreases the phosphorylation of STAT1(S727) and STAT5(S726) and reduces mRNA expression of MCL-1 and CCL2 in these cells. Its efficacy is validated in the MOLM-14 xenograft model, showing phosphorylation inhibition of STAT1(S727) and STAT5(S726) post-treatment. Pharmacokinetic studies in the MOLM-14 model reveal a dose-dependent inhibition of the STAT pathway. Both in vitro and in vivo studies confirm that MK256 effectively downregulates the STAT pathway.

AWD-G256 is anti-arrhythmic substance.AWD-G256 had no significant effect on stroke volume, lung pressure, or systemic blood pressure.